BishopJR, PavuluriMN: Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat, 4:55–68, 2008.
2.
BoganAM, BrownES, SuppesT: Efficacy of divalproex therapy for schizoaffective disorder. J Clin Psychopharmacol, 20:520–522, 2000.
3.
CleggA, YoungJB: Which medications to avoid in people at risk of delirium: A systematic review. Age Ageing, 40:23–29, 2011.
4.
ClemmensenL, VernalDL, SteinhausenHC: A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry, 12:150, 2012.
5.
DameguntaSR: Time matters!: When is the right time to estimate serum valproic acid levels?. Indian J Psychol Med, 36:349–350, 2014.
6.
DasS, ChatterjeeSS, MalatheshBC: Anticholinergic medications even in therapeutic range can cause recurrence of psychosis. Gen Psychiatr, 33:e100235, 2020.
7.
DelBelloMP, FosterKD, StrakowskiSM: Case report: Treatment of catatonia in an adolescent male. J Adolesc Health, 27:69–71, 2000.
8.
DhosscheDM, WachtelLE: Catatonia is hidden in plain sight among different pediatric disorders: A review article. Pediatr Neurol, 43:307–315, 2010.
9.
FinkM, TaylorMA: Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry, 30:1182–1185, 2006.
10.
FinkM, TaylorMA: Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge, Cambridge University Press, 2003.
11.
GreenWH, Padron-GayolM, HardestyAS, BassiriM: Schizophrenia with childhood onset: A phenomenological study of 38 cases. J Am Acad Child Adolesc Psychiatry, 31:968–976, 1992.
12.
HäßlerF, ReisO, WeirichS, HöppnerJ, PohlB, BuchmannJ: A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy. Z Kinder Jugendpsychiatr Psychother, 41:69–74, 2013.
13.
HauptmanAJ, BenjaminS: The differential diagnosis and treatment of catatonia in children and adolescents. Harv Rev Psychiatry, 24:379–395, 2016.
14.
HongIS, BishopJR: Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother, 44:1171–1180, 2010.
15.
LanderM, BastiampillaiT, SareenJ: Review of withdrawal catatonia: What does this reveal about clozapine?. Transl Psychiatry, 8:139, 2018.
16.
LiuZ, ZhengW, GaoS, QinZ, LiG, NingY: Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: A meta-analysis. Shanghai Arch Psychiatry, 27:331–340, 2015.
17.
MaddenK, HussainK, TaskerRC: Anticholinergic medication burden in pediatric prolonged critical illness: A potentially modifiable risk factor for delirium. Pediatr Crit Care Med, 19:917–924, 2018.
O'DonoghueB, MujanovicA, YoungS, BridsonT, MoraL, BismarkM, CocksJ, SiskindD, McGorryP: Physical health trajectories of young people commenced on clozapine. Ir J Psychol Med , 1–7, 2020.
20.
ReedRC, DuttaS: Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?. Ther Drug Monit, 28:413–418, 2006.
21.
RobbAS, LeeRH, CooperEB, SiedelJV, NusratN: Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents. J Child Adolesc Psychopharmacol, 18:99–107, 2008.
22.
SaffermanA, LiebermanJA, KaneJM, SzymanskiS, KinonB: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull, 17:247–261, 1991.
23.
Schimmelmann BennoG, Schmidt, StefanieJ, CarbonMaren, Correll, ChristophU: Treatment of adolescents with early-onset schizophrenia spectrum disorders: In search of a rational, evidence-informed approach. Curr Opin Psychiatry, 26:219–230, 2013.
24.
StroupTS, GrayN: Management of common adverse effects of antipsychotic medications. World Psychiatry, 17:341–356, 2018.
25.
SockalingamS, ShammiC, RemingtonG: Clozapine-induced hypersalivation: A review of treatment strategies. Can J Psychiatry, 52:377–384, 2007.
26.
ThakurA, JagadheesanK, DuttaS, SinhaVK: Incidence of catatonia in children and adolescents in a paediatric psychiatric clinic. Aust N Z J Psychiatry, 37:200–203, 2003.
27.
WangM, TongJH, ZhuG, LiangGM, YanHF, WangXZ: Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr Res, 138:54–57, 2012.
28.
WeaverLA, De LeónDD, Borgmann-WinterK, CoffeyBJ: Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder. J Child Adolesc Psychopharmacol, 20:153–157, 2010.
29.
YusufiB, MukherjeeS, FlanaganR, PatonC, DunnG, PageE, BarnesTRE: Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol, 22:238–243, 2007.
